Companies › Kymera Therapeutics
2 active drug programs in 5 registered trials: 3 Phase 2, 2 Phase 1; Other, Immunology, Respiratory; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| KT-621 Cereblon E3 ubiquitin ligase ligand (CRBN-binding degrader) | – | Phase 2 | Atopic Dermatitis; Eosinophilic Asthma; Asthma (Diagnosis); Healthy Participants | Apr 2027 |
| KT-579 | – | Phase 1 | Healthy Participants | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07412288 | KT-579 | Phase 1 | Healthy Participants | Other | Aug 2026 |
| NCT07823205 | KT-621 | Phase 1 | Healthy Participants | Other | Apr 2027 |
| NCT07217015 | KT-621 | Phase 2 | Atopic Dermatitis | Immunology | Jun 2027 |
| NCT07323654 | KT-621 | Phase 2 | Eosinophilic Asthma | Respiratory | Dec 2027 |
| NCT07677059 | KT-621 | Phase 2 | Asthma (Diagnosis) | Respiratory | Dec 2028 |
Cash and short-term investments of $971m on 2026-09-30; operating cash outflow about $296m a year; runway about 39 months at that burn, to Jan 2030; 3 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Shattuck Labs QED Therapeutics, a BridgeBio company Oruka Therapeutics Shanghai Synvida Biotechnology Monte Rosa Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.